Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$139.02 USD

139.02
2,616,684

+10.04 (7.78%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $139.40 +0.38 (0.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Illumina (ILMN) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 38.97% and 0.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Illumina (ILMN) This Earnings Season?

by Zacks Equity Research

Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Illumina (ILMN) is likely to have gained during the first quarter on the back of robust performance of the sequencing consumable segment.

Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BMY vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

BMY vs. ILMN: Which Stock Is the Better Value Option?

Company News for Apr 7, 2021

by Zacks Equity Research

Companies in The News Are: ILMN, NVAX, MRNA, BP.

Illumina (ILMN) Preliminary Q1 Revenues Rebound, '21 View Up

by Zacks Equity Research

Illumina's (ILMN) revenue improvement in the first quarter is likely to have been boosted by on-going business recovery.

Illumina (ILMN) Moves 4.1% Higher: Will This Strength Last?

by Zacks Equity Research

Illumina (ILMN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Illumina's (ILMN) Grail Merger in Trouble as FTC Files Suit

by Zacks Equity Research

According to FTC, the Illumina (ILMN) and Grail merger will diminish the scope of innovation in the U.S. market for MCED tests.

Why You Should Hold on to Illumina (ILMN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of products.

Illumina's (ILMN) Expanded NIPT Coverage Study Outcome Favorable

by Zacks Equity Research

Illumina's (ILMN) coverage for pregnant women under the age of 35 will provide access of NIPT to thousands of women with minimal financial impact.

Illumina (ILMN) NGS-Based Platform Approved for Use in Russia

by Zacks Equity Research

Illumina and R-Pharm's in-vitro diagnostics platform registration will drive the expansion of Next Generation Sequencing-based clinical diagnostics across Russia.

Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Illumina (ILMN) closed the most recent trading day at $398.85, moving -0.19% from the previous trading session.

Myriad Genetics (MYGN) Collaborates to Advance Oncology Care

by Zacks Equity Research

Myriad Genetics (MYGN) to provide a comprehensive offering utilizing germline genetic testing and somatic tumor profiling via latest collaboration with Intermountain Precision Genomics.

CHRS or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CHRS vs. ILMN: Which Stock Is the Better Value Option?

Illumina (ILMN) Sequencing & Microarray Sales Hurt by Pandemic

by Zacks Equity Research

Seasonality in DTC functionality also continues to erode Illumina's (ILMN) microarray sales.

Myriad Genetics' (MYGN) Prolaris Test Study Outcome Favorable

by Zacks Equity Research

Myriad Genetics' (MYGN) new study combines a Prolaris molecular risk score approach with a clinical model for predicting a patient's benefit from androgen deprivation therapy.

Illumina (ILMN) Q4 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Illumina (ILMN) exhibits dismal performance by the Service & Other segment in the fourth quarter of 2020 due to pandemic-led business disruptions.

Illumina (ILMN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 0.83% and 0.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

New Study Favors Myriad Genetics' (MYGN) GeneSight Test

by Zacks Equity Research

Myriad Genetics' (MYGN) GeneSight Psychotropic test is better for predicting patient outcomes and medication blood levels than single-gene testing, per new study.

Illumina (ILMN) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Illumina (ILMN) is likely to have gained during the fourth quarter from the robust performance of sequencing consumable segment.

Illumina (ILMN) New Collaboration to Aid Genomics Startups

by Zacks Equity Research

Illumina (ILMN) partners with Sequoia Capital China to set up a genomics-focused startup incubator in China.

Baidu, Illumina, American Axle & Manufacturing, International Paper and KB Home highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Baidu, Illumina, American Axle & Manufacturing, International Paper and KB Home highlighted as Zacks Bull and Bear of the Day

Kevin Cook headshot

Bear of the Day: Illumina (ILMN)

by Kevin Cook

Maker of premier next-gen genomic sequencing technology lowers guidance but shares make new highs

Illumina (ILMN) is in Overbought Territory: What's Next?

by Zacks Equity Research

Illumina (ILMN) has moved higher as of late, but there could definitely be trouble on the horizon for this company.